Tendyne Raises $25 Million
in Series C
Proceeds will be used for validation of Tendyne’s novel Transcatheter Mitral Valve Implant to treat mitral regurgitation, including forthcoming clinical trials.
©2014 Tendyne Holdings, Inc.
Tendyne’s products are not approved for investigational use or sale in the United States.